In the Liraglutide Effects in Atrial Fibrillation (LEAF) Study, researchers at the University of Miami Miller School of Medicine, led by Jeffrey Goldberger, M.D., cardiac electrophysiologist and professor of cardiovascular medicine at the Miller School, found that adding the GLP1 receptor agonist liraglutide to a structured riskfactor modification program significantly improved freedom from AFib or atrial flutter one year after catheter ablation in overweight and obese patients
Free Radic Biol Med 47:13291338 Kowalec P, Grynberg M, Pajak B, Socha A, Winiarska K, Fronk J, Kurlandzka A (2015) Newly identified protein Imi1 affects mitochondrial integrity and glutathione homeostasis in Saccharomyces cerevisiae
2-3 month courses to be repeated every 2-3 months
Protocols commonly monitor GI adverse events (e.g., nausea) concurrent with motor effects during titration [2,3]